BioNeex Interviews
Interview with the CSO of Bright Minds Biosciences, Dr. Jan Torleif Pedersen
May 31, 2023
Clinical Stage
Bright Minds Biosciences is a US based biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain.
Bright Minds Biosciences has a strong translational science foundation to support its drug development. It has a rich and growing library of proprietary compounds targeting the 5-HT2C, 5-HT2A/C and 5-HT2A receptors. By using intelligent drug design and advanced molecular modeling, and scientifically rigorous evaluation in pre-clinical models of brain function at the network level, the team can select compounds with the best activity profile for advancing into clinical trials in patients.
Back 
Interview URL has been copied in the clipboard